RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Aiming, FWIW, I added 2 more names to my list of stocks for the longer term (now up to 20). In addition to Durect, I also added Medarex (a no brainer for the longer term).

BTW, concerning Durect, I see that in the Sufentanil program with Endo Pharma, Durect gets a big 30-40% royalty on US/Canada sales, and Durect retains the full rights to the rest of the world. Sufentanil is targeting the $2.2 Bil Duragesic market (J+J), where J+J gets approx $1.4 Bil in the US/Canada, and a surprisingly huge $800 mil/year outside the US! So bottom line, Durect will have numerous huge revenue sources - 1) their in-house long acting Bupivicaine program (Bil+), 2) the partnered Sufentanil program (Bil/year potential also), and 3) the Remoxy and other PTIE/King program royalties, and those from the Voyager AD program. And long-acting Bupivicaine, Sufentanil, and Remoxy are all programs that are extremely likely to be approved and strongly accepted by physicians. I really like Durect, and their management seems very sharp.